TENILSETAM

Details

Stereochemistry	RACEMIC
Molecular Formula	C8H10N2OS
Molecular Weight	182.243
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C1NCCNC1C2=CC=CS2

InChI

InChIKey=BBACKDMGYMXYLE-UHFFFAOYSA-N

InChI=1S/C8H10N2OS/c11-8-7(9-3-4-10-8)6-2-1-5-12-6/h1-2,5,7,9H,3-4H2,(H,10,11)

HIDE SMILES / InChI

Molecular Formula	C8H10N2OS
Molecular Weight	182.243
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25025046 | https://www.ncbi.nlm.nih.gov/pubmed/16601840

Tenilsetam (CAS 997: ( /-)-3-(2-thienyl)-2-piperazinone), a cognition-enhancing drug successfully used for the treatment of patients suffering from Alzheimer's disease. According to the mechanism proposed, it inhibits advanced glycation end-product (AGE) formation. The beneficial effect of tenilsetam in Alzheimer's disease could come from the interference with AGE-derived crosslinking of amyloid plaques and a decreased inflammatory response to diminished activation of phagocytosing microglia. In addition was shown, that the long-term treatment with tenilsetam inhibited the formation of acellular capillaries without correcting pericyte loss. Was suggested that tenilsetam could be useful for the treatment of early diabetic retinopathy, but then these studies were discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Advanced glycation end-product 4 Target ID: Advanced glycation end-product Sources: https://www.ncbi.nlm.nih.gov/pubmed/7748463	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Alzheimer’s disease 278 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25025046	Primary		Phase I 438	Unknown Approved Use Unknown
Diabetic retinopathy 17 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16601840	Primary		Preclinical	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
2.03 μg/mL EXPERIMENT https://doi.org/10.1002/ddr.430090203	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	TENILSETAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.33 μg/mL EXPERIMENT https://doi.org/10.1002/ddr.430090203	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TENILSETAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
9.03 μg/mL EXPERIMENT https://doi.org/10.1002/ddr.430090203	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TENILSETAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
31.97 μg × h/mL EXPERIMENT https://doi.org/10.1002/ddr.430090203	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	TENILSETAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
65.98 μg × h/mL EXPERIMENT https://doi.org/10.1002/ddr.430090203	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TENILSETAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
146.99 μg × h/mL EXPERIMENT https://doi.org/10.1002/ddr.430090203	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TENILSETAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
18.31 h EXPERIMENT https://doi.org/10.1002/ddr.430090203	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	TENILSETAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
18.39 h EXPERIMENT https://doi.org/10.1002/ddr.430090203	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TENILSETAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
21.84 h EXPERIMENT https://doi.org/10.1002/ddr.430090203	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TENILSETAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B3-032355	http://www.3bsc.com/index/pro_info.php?id=53619
AA Blocks	AA008F6E	http://www.aablocks.com/goods/Goods/detail?id=AA008F6E
AHH Chemical co.,ltd	MT-39219	http://www.ahhchemical.com/product/MT-39219.html
Alfa Chemistry	86696-86-8	https://www.alfa-chemistry.com/cas_86696-86-8.htm
Ambinter	Amb17233931	http://www.ambinter.com/reference/17233931
Angene	AGN-PC-0WH9CC	http://www.angenechemical.com/productshow/AGN-PC-0WH9CC.html
Aurora Fine Chemicals LLC	A02.248.219	http://online.aurorafinechemicals.com/info?ID=A02.248.219
Aurora Fine Chemicals LLC	K11.126.055	http://online.aurorafinechemicals.com/info?ID=K11.126.055
Aurum Pharmatech LLC	NE35533	http://www.Aurumpharmatech.com/Product/ProductDetails/NE35533
Axon MedChem	1470	https://www.axonmedchem.com/product/1470
BLD Pharm	BD148187	http://www.bldpharm.com/products/86696-86-8.html
BOC Sciences	86696-86-8	https://www.bocsci.com/tenilsetam-cas-86696-86-8-item-36557.html
ChemMol	49410319	http://www.chemmol.com/chemmol/49410319.html
Chemspace	CSSB00000764337	https://chem-space.com/CSSB00000764337
Enamine	EN300-93479	https://www.enaminestore.com/catalog/EN300-93479
Enamine	Z1270446302	https://www.enaminestore.com/catalog/Z1270446302
eNovation Chemicals	D144244	https://www.enovationchem.com/ProductDetails.asp?ProductID=D144244
Lab Network	LN01261624	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01261624
Matrix Scientific	134199	https://www.matrixscientific.com/134199.html
mcule	MCULE-7988720436	https://mcule.com/MCULE-7988720436
MolPort	MolPort-000-006-560	https://www.molport.com/shop/molecule-link/MolPort-000-006-560
Smolecule	S570826	https://www.smolecule.com/products/s570826
Synblock Inc	AB07563	http://www.synblock.com/product/86696-86-8.html
THE BioTek	bt-369400	https://www.thebiotek.com/product/others/bt-369400

PubMed

Title	Date	PubMed
Chelating activity of advanced glycation end-product inhibitors.	2001-12-28	11677237
The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation.	1994	7748463

Patents

Sample Use Guides

In Vivo Use Guide

a pilot trial for Alzheimer's disease (AD) patients. Over a 3-month period at 150 mg/day doses, AD patients showed significant improvements in the favorability judgment task (FJT) and reaction time

Route of Administration: Oral

In Vitro Use Guide

In the experiments with human neuroblastoma SH-SY5Y cells, incubated with methylglyoxal which was preincubated with tenilsetam for 2 or 24 hours, tenilsetam completely nullified the toxicity of methylglyoxal at both time points.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:01:40 GMT 2025` Edited by `admin` on `Mon Mar 31 18:01:40 GMT 2025`
Record UNII	O4Q7XM74N6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TENILSETAM

Official Name

English

tenilsetam [INN]

Preferred Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1509